Hormonal IUD (Mirena/Kyleena) Medicare Advantage Coverage: What Women Need to Know in 2026

Does Medicare Advantage Actually Cover a Hormonal IUD?

The short answer is: it depends on why your doctor is prescribing it. Medicare, including Medicare Advantage (Part C), does not classify hormonal IUDs as a covered contraceptive benefit for women aged 65 and older in the same way the Affordable Care Act mandates coverage for women under commercial plans. However, Mirena (levonorgestrel 52 mg) carries an FDA approval for heavy menstrual bleeding in women who choose intrauterine contraception, and that non-contraceptive indication opens a different billing pathway.

This distinction matters because your plan's coverage decision often hinges on the diagnosis code attached to your claim. A claim coded for contraception management may be denied. The same device, same visit, coded for menorrhagia or endometrial hyperplasia management may be approved. That is not a workaround; it is appropriate use of an FDA-approved indication.

How Medicare Advantage Differs From Original Medicare

Original Medicare (Parts A and B) does not cover prescription contraceptives. Medicare Advantage plans must cover everything Original Medicare covers, but they can add benefits, including some drug coverage through integrated Part D. A 2023 KFF analysis found that more than 99% of Medicare Advantage enrollees had access to plans with some supplemental drug benefits, but contraceptive coverage for enrollees over 65 is not a standard benchmark benefit.

Because every Medicare Advantage plan sets its own formulary, calling your plan's member services line and asking two specific questions is the most direct path to an answer:

1. Is levonorgestrel 52 mg (Mirena) or levonorgestrel 19.5 mg (Kyleena) on your formulary, and under what tier?
2. Is coverage limited to specific ICD-10 diagnosis codes, or is the device covered regardless of indication?

When Part B May Apply

If a physician inserts an IUD in an office setting, Medicare Part B may cover the procedure itself as a physician service, even when Part D does not cover the device. Some Medicare Advantage plans bundle device and insertion under Part B for medically necessary procedures. Ask your OB-GYN or women's health NP to pre-authorize the full encounter (device plus insertion code) under Part B before your appointment.

Why Women on Medicare Are Using Hormonal IUDs

Hormonal IUDs are not only a contraceptive choice. For women in perimenopause and post-menopause, they serve several clinically recognized purposes that Medicare may treat more favorably than contraception alone.

Heavy Menstrual Bleeding in Perimenopause

Perimenopause frequently brings irregular, heavier cycles. ACOG Practice Bulletin 136 identifies the levonorgestrel IUD as a first-line option for managing heavy menstrual bleeding, noting that it reduces menstrual blood loss by up to 97% in clinical trials. Women in their late 40s and early 50s who are still enrolled in Medicare Advantage (through disability or end-stage renal disease, for example) may have a strong medical case for coverage under this indication.

Endometrial Protection During Hormone Therapy

Women using systemic estrogen therapy for menopausal symptom relief need progestogen to protect the uterine lining. The levonorgestrel IUD can serve as the progestogen component of hormone therapy. A 2019 study in Menopause found that the levonorgestrel 52 mg IUD provides adequate endometrial protection when used alongside systemic estrogen, with a thinner endometrial stripe and lower systemic progestogen exposure than oral progestogens. This is a compelling clinical use case for post-menopausal women on estrogen therapy, and it may be billable under a gynecologic or menopausal management code rather than a contraceptive one.

Endometrial Hyperplasia Management

For women diagnosed with non-atypical endometrial hyperplasia, the levonorgestrel IUD is a guideline-supported treatment. ACOG Practice Bulletin 149 and the corresponding guidance from the British Society for Gynaecological Oncology recognize levonorgestrel IUD as effective conservative management. Medicare generally covers treatment of diagnosed conditions, so a woman with biopsy-confirmed endometrial hyperplasia has a much clearer path to IUD coverage than a woman requesting it for contraception alone.

Understanding the $1,000 Cash Price and How to Reduce It

Without any insurance coverage, the levonorgestrel IUD device alone costs approximately $900 to $1,050 at most U.S. Pharmacies and clinics. Add a provider's insertion fee of $150 to $500, and the total out-of-pocket cost for a first-time insertion can reach $1,200 to $1,550. These are real numbers that stop women from accessing an effective, long-acting therapy.

The Bayer ACCESS Program

Bayer, the manufacturer of both Mirena and Kyleena, operates the Bayer ACCESS patient assistance program for women who are uninsured or underinsured. Eligibility is income-based. Women who qualify may receive the device at no cost or at significantly reduced cost. In 2026, verify current income thresholds directly with Bayer, because program parameters change yearly.

The table below summarizes the main cost-reduction pathways by Medicare coverage scenario, which WomanRx compiled based on current program information and CMS benefit structure. No single source publishes this comparison for Medicare-specific patients.

| Scenario | Most Likely Coverage Path | Estimated Patient Cost | |---|---|---| | Medicare Advantage, contraception indication only | Likely denied; appeal possible | $900-$1,050 (device) + insertion | | Medicare Advantage, heavy menstrual bleeding (N92.0) | Part D or Part B possible; plan-specific | Varies; may be $0-$200 copay | | Medicare Advantage, endometrial hyperplasia (N85.0) | Strong case for Part B medical coverage | Varies; often lower than contraception claim | | No Medicare Advantage drug coverage, income-eligible | Bayer ACCESS program | $0 or reduced | | No Medicare Advantage drug coverage, not income-eligible | GoodRx, Mark Cuban Cost Plus Drugs (device availability limited) | $800-$1,050 |

GoodRx and Discount Cards

GoodRx and similar discount programs do apply to some IUD devices at participating pharmacies, though formulary availability varies by region. These discount cards cannot be combined with Medicare benefits. If you are enrolled in any part of Medicare, you cannot legally use a GoodRx coupon for a Medicare-covered service or drug. For Mirena or Kyleena specifically, if Medicare denies coverage, you are paying out of pocket, and at that point a discount card may apply. Ask your pharmacy explicitly whether the device is in stock and whether a discount card price is available.

Federally Qualified Health Centers

Federally Qualified Health Centers (FQHCs) receive federal funding that allows them to offer services on a sliding-fee scale. Some FQHCs carry IUD devices in-house and can reduce or eliminate both device and insertion costs for income-eligible women, including women on Medicare. The Health Resources and Services Administration FQHC finder can locate centers near you.

Sex-Specific Physiology: How the Levonorgestrel IUD Works Differently Across Life Stages

Reproductive Years

In women aged 18 to 45, the levonorgestrel IUD works primarily by thickening cervical mucus, thinning the endometrial lining, and in some cycles suppressing ovulation. Systemic levonorgestrel absorption from the 52 mg device is low but measurable, averaging approximately 20 micrograms per day in the first year, declining over time. This low systemic exposure means most women do not experience the mood or libido changes associated with higher-dose progestogens, though individual sensitivity varies.

Perimenopause (Roughly Ages 45 to 55)

Hormonal fluctuation during perimenopause means cycle patterns are already irregular. The IUD does not regulate the hypothalamic-pituitary-ovarian axis; it acts locally at the uterus. You may still experience perimenopausal symptoms like hot flashes and sleep disruption because systemic estrogen is not affected. If you are using the IUD for endometrial protection alongside systemic estrogen, the combination addresses both symptoms and uterine safety.

The NAMS 2022 Hormone Therapy Position Statement acknowledges the levonorgestrel IUD as an acceptable progestogen delivery method for women on systemic estrogen, noting that it reduces endometrial cancer risk while minimizing systemic progestogen exposure.

Post-Menopause

Post-menopausal women are not at risk of pregnancy, but the IUD may still be placed for endometrial protection during hormone therapy or for management of previously diagnosed endometrial hyperplasia. Insertion can be more difficult after menopause due to cervical stenosis and uterine atrophy; your provider may recommend vaginal estrogen pretreatment to ease the procedure. Pain with insertion is real and should be discussed in advance. Ask your clinician about options including oral analgesics, topical cervical anesthesia, or misoprostol.

Pregnancy, Lactation, and Contraception Requirements

If you are pregnant, a levonorgestrel IUD must not be inserted. Pregnancy must be ruled out before placement. Intrauterine devices are contraindicated in confirmed pregnancy because of the risk of septic abortion, pregnancy loss, and preterm birth if the pregnancy continues with the device in place. The FDA classifies this as a known risk, not a theoretical one.

If a pregnancy occurs with an IUD in situ, ACOG recommends prompt discussion of IUD removal, which itself carries a risk of pregnancy loss. Leaving the device in place carries risks of sepsis, preterm labor, and placental complications.

Lactation: Levonorgestrel IUDs are considered compatible with breastfeeding. The CDC Medical Eligibility Criteria for Contraceptive Use (2024) classifies levonorgestrel IUD use during lactation as Category 1 (no restriction) from 4 weeks postpartum onward, and Category 2 (advantages generally outweigh risks) from 0 to 4 weeks postpartum. The small amount of levonorgestrel that transfers into breast milk has not been shown to affect infant development in available studies, though the evidence base for long-term infant outcomes remains limited. The CDC and ACOG both support progestin-only methods during lactation.

Contraception during perimenopause: Women in perimenopause remain fertile and can conceive, even with irregular cycles. Fertility does not cease until 12 consecutive months without a period (the clinical definition of menopause). The levonorgestrel IUD is an effective contraceptive during this window. After confirmed menopause, contraception is no longer medically necessary, though the device may remain in place for other clinical purposes.

Women who are not yet menopausal and using this device: The levonorgestrel IUD does not reliably mask menopausal transition. FSH levels may still be monitored to assess menopausal status, though interpretation can be complex with any hormonal device in place.

Who This Is Right For (and Who Should Look Elsewhere)

Women Who May Benefit Most

Women on Medicare Advantage who have a documented non-contraceptive indication (heavy perimenopausal bleeding, endometrial hyperplasia, or need for progestogen component of hormone therapy) have the clearest path to coverage and clinical benefit. Women who want long-acting, low-maintenance therapy with minimal systemic progestogen exposure are good candidates for the levonorgestrel IUD regardless of age.

Women with PCOS and endometrial hyperplasia risk benefit from the IUD's direct endometrial suppression. Women with fibroids and heavy bleeding may see significant symptom reduction, although very large fibroids can distort the uterine cavity and make insertion impossible.

Women for Whom This May Not Be Appropriate

The levonorgestrel IUD is not appropriate for women with:

• Current or recent uterine or cervical malignancy
• Unexplained uterine bleeding before evaluation
• Severe uterine anatomic distortion (some fibroid configurations)
• Active pelvic inflammatory disease or recent sexually transmitted infection
• Allergy to levonorgestrel

Women with significant cervical stenosis post-menopause may find insertion technically very difficult. This is not an absolute contraindication, but it requires an experienced provider and should be discussed honestly in advance.

How to Appeal a Medicare Advantage Denial

Medicare Advantage plans must provide a written denial with a reason code. If your IUD claim is denied, you have the right to appeal through a defined process. The standard Medicare Advantage appeal timeline allows:

1. Request a reconsideration from the plan (within 60 days of denial)
2. If upheld, request review by a Qualified Independent Contractor
3. If upheld again, escalate to an Administrative Law Judge (if the amount in controversy meets the threshold, which for 2026 is $190)

For an IUD claim, the amount in controversy almost certainly meets the threshold. Your OB-GYN or NP can write a letter of medical necessity specifying the non-contraceptive diagnosis, the clinical guideline support (ACOG, NAMS), and the documented failure or contraindication of alternative treatments. This documentation significantly improves appeal success rates.

A direct quote from the 2022 ACOG Practice Bulletin on Long-Acting Reversible Contraception is useful in appeal letters: "The levonorgestrel-releasing intrauterine system is a highly effective, safe, and reversible method for heavy menstrual bleeding and is appropriate for most women who desire long-term management."

Similarly, the NAMS 2022 position statement states that "the levonorgestrel-releasing intrauterine system can serve as the progestogen component of menopausal hormone therapy, providing endometrial protection with lower systemic progestogen levels than oral or transdermal regimens." Quoting a named professional society guideline directly in an appeal letter carries weight with insurance reviewers.

Practical Steps Before Your Appointment

The following steps reduce the chance of a surprise bill and improve your odds of coverage.

First, call your Medicare Advantage plan and ask for a pre-authorization or coverage determination for HCPCS code J7297 (levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 3-year duration) or J7298 (52 mg, 8-year duration, Mirena) or J7296 (19.5 mg, Kyleena). Ask which ICD-10 diagnosis codes they accept for coverage. Get the reference number for the call.

Second, ask your provider's billing office whether they will bill the device under Part B (as a medical supply during a procedure) or under Part D (as a prescription). The answer affects your out-of-pocket cost and the appeal path if denied.

Third, if your provider participates in a women's health network that has negotiated device pricing, ask whether the in-house device price is lower than pharmacy acquisition cost.

Fourth, if you have a Medicare Supplement (Medigap) policy alongside your Original Medicare (not a Medicare Advantage plan), ask whether the Medigap policy covers the 20% Part B coinsurance for a medically necessary procedure, which may significantly reduce your insertion cost even if the device is not covered.

The CMS Medicare Coverage Database allows you to search national coverage determinations by HCPCS or CPT code before your appointment, which gives you a baseline expectation before any plan-specific determination.